Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jan;15(1):26-8.
doi: 10.1016/S1474-4422(15)00320-8. Epub 2015 Nov 6.

MRI quantifies neuromuscular disease progression

Sean C Forbes  1 , Rebecca J Willcocks  1 , William D Rooney  2 , Glenn A Walter  3 , Krista Vandenborne  4
Affiliations
Comment

MRI quantifies neuromuscular disease progression

Sean C Forbes et al. Lancet Neurol. 2016 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

Figure
Figure. MRI and magnetic resonance spectroscopy of skeletal muscle in Duchenne muscular dystrophy
(A) Magnetic resonance spin echo axial image of the lower leg of an 11-year-old boy with Duchenne muscular dystrophy. The white box indicates the position of voxel placement in which proton magnetic resonance spectroscopy data were obtained from the soleus muscle. (B) Single voxel spectroscopic relaxometry data were acquired using a non-linear increase in echo time (range 11–288 ms). Fitting the decay curve of the 1H2O peak to a mono-exponential model enabled a high confidence measure of 1H2O transverse relaxation time independent of lipid. In this example, 1H2O transverse relaxation time was calculated to be 36·5 ms in the boy with Duchenne muscular dystrophy, which is substantially longer than that of a typical unaffected boy of a similar age (27–29 ms). The proton spectra are displayed with water referenced at 4·7 parts per million (ppm) and the smaller resonances reported between 0·5 ppm and 2·8 ppm are from lipid protons. Images collected as part of the Imaging DMD study.
See this image and copyright information in PMC

Comment on

References

    1. Willcocks RJ, Arpan IA, Forbes SC, et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Dis. 2014;24:393–401. - PMC - PubMed
    1. Bonati U, Hafner P, Schädelin S, et al. Quantitative muscle MRI: a powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Dis. 2015;25:679–85. - PubMed
    1. Willis TA, Hollingsworth KG, Coombs A, et al. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One. 2013;8:e70993. - PMC - PubMed
    1. Morrow JM, Sinclair CDJ, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2015 published online Nov 5. http://dx.doi.org/10.1016/S1474-4422(15)00242-2. - DOI - PMC - PubMed
    1. Hoffman EP, Connor EM. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov Med. 2013;16:233–39. - PubMed

Publication types